InvestorsHub Logo
Followers 4
Posts 929
Boards Moderated 0
Alias Born 08/15/2006

Re: InTheTrenches post# 42895

Tuesday, 01/23/2018 10:22:35 PM

Tuesday, January 23, 2018 10:22:35 PM

Post# of 48316
Dr. Algazi comment (principal investigator of Phase 2b EP IL-12 + Keytruda):

When he was asked what he predicts the ORR would be on the total population, not just patients refractory to anti-PD1 inhibitors, his answer was simply... "75%". (from Twitter--POUNDtheROCK author)


That is, he predicts ORR of tavo + Keytruda will be significantly better than 1st line treatment (Opdivo) in unresectable melanoma.